[HTML][HTML] African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody …
N Arisue, NMQ Palacpac, EH Ntege, A Yeka… - Frontiers in Cellular …, 2022 - frontiersin.org
BK-SE36, based on Plasmodium falciparum serine repeat antigen 5 (SERA5), is a blood-
stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in …
stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in …
African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody …
N Arisue, NMQ Palacpac, EH Ntege… - Frontiers in cellular …, 2022 - pubmed.ncbi.nlm.nih.gov
BK-SE36, based on Plasmodium falciparum serine repeat antigen 5 (SERA5), is a blood-
stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in …
stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in …
[PDF][PDF] African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere
J Li, PM De Luca, N Arisue, NMQ Palacpac, N Arisue… - ir.library.osaka-u.ac.jp
Despite unprecedented gains in malaria control, progress has stalled in recent years.
Children under 5 years old in sub-Saharan Africa continue to shoulder a disproportionate …
Children under 5 years old in sub-Saharan Africa continue to shoulder a disproportionate …
African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody …
N Arisue, NMQ Palacpac, EH Ntege, A Yeka… - Frontiers in Cellular …, 2022 - cir.nii.ac.jp
抄録< jats: p> BK-SE36, based on< jats: italic> Plasmodium falciparum</jats: italic> serine
repeat antigen 5 (SERA5), is a blood-stage malaria vaccine candidate currently being …
repeat antigen 5 (SERA5), is a blood-stage malaria vaccine candidate currently being …
[PDF][PDF] African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere
J Li, PM De Luca, N Arisue, NMQ Palacpac, N Arisue… - academia.edu
Despite unprecedented gains in malaria control, progress has stalled in recent years.
Children under 5 years old in sub-Saharan Africa continue to shoulder a disproportionate …
Children under 5 years old in sub-Saharan Africa continue to shoulder a disproportionate …
[PDF][PDF] African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere
J Li, PM De Luca, N Arisue, NMQ Palacpac, N Arisue… - media.malariaworld.org
Despite unprecedented gains in malaria control, progress has stalled in recent years.
Children under 5 years old in sub-Saharan Africa continue to shoulder a disproportionate …
Children under 5 years old in sub-Saharan Africa continue to shoulder a disproportionate …
African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody …
N Arisue, NMQ Palacpac, EH Ntege, A Yeka… - 2022 - agris.fao.org
BK-SE36, based on Plasmodium falciparum serine repeat antigen 5 (SERA5), is a blood-
stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in …
stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in …
African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody …
N Arisue, NMQ Palacpac, EH Ntege… - Frontiers in Cellular …, 2022 - europepmc.org
BK-SE36, based on Plasmodium falciparum serine repeat antigen 5 (SERA5), is a blood-
stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in …
stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in …
African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody …
N Arisue, NMQ Palacpac, EH Ntege… - Frontiers in Cellular …, 2022 - search.ebscohost.com
BK-SE36, based on Plasmodium falciparum serine repeat antigen 5 (SERA5), is a blood-
stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in …
stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in …
African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody …
N Arisue, NMQ Palacpac, EH Ntege, A Yeka… - 2022 - cabidigitallibrary.org
BK-SE36, based on Plasmodium falciparum serine repeat antigen 5 (SERA5), is a blood-
stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in …
stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in …